These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656 [TBL] [Abstract][Full Text] [Related]
24. Adherence to follow-up recommendations for dogs with apocrine gland anal sac adenocarcinoma: A multicentre retrospective study. Chambers AR; Skinner OT; Mickelson MA; Schlag AN; Butler JR; Wallace ML; Moyer AL; Vinayak A; Samuel N; Kennedy KC; Oakes KE; Scharf VF; Parker LA; Wustefeld-Janssens BG Vet Comp Oncol; 2020 Dec; 18(4):683-688. PubMed ID: 32266757 [TBL] [Abstract][Full Text] [Related]
25. The role of toceranib phosphate in dogs with non-mast cell neoplasia: A systematic review. Frezoulis P; Harper A Vet Comp Oncol; 2022 Jun; 20(2):362-371. PubMed ID: 34981886 [TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma. Kim C; Matsuyama A; Mutsaers AJ; Woods JP Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355 [TBL] [Abstract][Full Text] [Related]
27. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014-2017). Musser ML; Taikowski KL; Johannes CM; Bergman PJ BMC Vet Res; 2018 Sep; 14(1):272. PubMed ID: 30176869 [TBL] [Abstract][Full Text] [Related]
28. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma. Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia. Alonso-Miguel D; García-San José P; González Sanz S; Clarés Moral I; Pérez-Alenza MD N Z Vet J; 2021 Jul; 69(4):234-239. PubMed ID: 33944682 [TBL] [Abstract][Full Text] [Related]
30. Surgery of metastatic anal sac adenocarcinoma in five dogs. Hobson HP; Brown MR; Rogers KS Vet Surg; 2006 Apr; 35(3):267-70. PubMed ID: 16635006 [TBL] [Abstract][Full Text] [Related]
32. Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. Brown RJ; Newman SJ; Durtschi DC; Leblanc AK Vet Comp Oncol; 2012 Mar; 10(1):74-9. PubMed ID: 22235855 [TBL] [Abstract][Full Text] [Related]
33. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs. Tjostheim SS; Stepien RL; Markovic LE; Stein TJ J Vet Intern Med; 2016 Jul; 30(4):951-7. PubMed ID: 27149912 [TBL] [Abstract][Full Text] [Related]
34. Minimal complications observed with a modified surgical approach for treatment of canine anal sac neoplasia. Chen CL; Lapsley JM; Selmic LE J Am Vet Med Assoc; 2021 Dec; 260(S1):S59-S64. PubMed ID: 34914627 [TBL] [Abstract][Full Text] [Related]
35. Retrospective evaluation of toceranib phosphate (Palladia) in the treatment of canine carcinomatosis and mesothelioma. Hicks KA; Leeper HJ; Curran KM Vet Comp Oncol; 2024 Jun; 22(2):245-254. PubMed ID: 38622074 [TBL] [Abstract][Full Text] [Related]
36. Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy. Emms SG Aust Vet J; 2005 Jun; 83(6):340-3. PubMed ID: 15986909 [TBL] [Abstract][Full Text] [Related]
37. Temporally separated bilateral anal sac gland carcinomas in four dogs. Bowlt KL; Friend EJ; Delisser P; Murphy S; Polton G J Small Anim Pract; 2013 Aug; 54(8):432-6. PubMed ID: 23659267 [TBL] [Abstract][Full Text] [Related]
38. Minimal late radiation toxicity and transient early toxicity following postoperative definitive intent conformal radiation therapy (20 × 2.5 Gy) for canine apocrine gland anal sac adenocarcinoma. Williams C; Parys M; Handel I; Serra JC; Lawrence J Vet Radiol Ultrasound; 2022 Mar; 63(2):224-233. PubMed ID: 34904326 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. Yancey MF; Merritt DA; Lesman SP; Boucher JF; Michels GM J Vet Pharmacol Ther; 2010 Apr; 33(2):162-71. PubMed ID: 20444041 [TBL] [Abstract][Full Text] [Related]
40. Three-dimensional conformal versus non-graphic radiation treatment planning for apocrine gland adenocarcinoma of the anal sac in 18 dogs (2002-2007). Keyerleber MA; Gieger TL; Erb HN; Thompson MS; McEntee MC Vet Comp Oncol; 2012 Dec; 10(4):237-45. PubMed ID: 22235910 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]